Indian Journal of Medical Biochemistry

Register      Login

VOLUME 23 , ISSUE 1 ( January-April, 2019 ) > List of Articles

Original Article

Elevated Luteinizing Hormone, Testosterone and Free Triiodothyronine with Increase in Body Mass Index in Polycystic Ovary Syndrome

Palani S Mohanraj, Angel M Sylus

Keywords : Gonadotropins, Luteinizing hormone, Obesity, Polycystic ovary syndrome, Testosterone, Thyroxine

Citation Information : Mohanraj PS, Sylus AM. Elevated Luteinizing Hormone, Testosterone and Free Triiodothyronine with Increase in Body Mass Index in Polycystic Ovary Syndrome. Indian J Med Biochem 2019; 23 (1):203-206.

DOI: 10.5005/jp-journals-10054-0086

License: CC BY-NC 4.0

Published Online: 01-04-2019

Copyright Statement:  Copyright © 2019; The Author(s).


Abstract

Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women in the reproductive age group. The association of testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH) and thyroid hormones in obese PCOS women are not clear. Hence, the present study was performed to assess the serum levels of gonadotrophins, testosterone and thyroid hormones in obese and nonobese PCOS women. Materials and methods: Sixty-three patients (41 obese and 22 nonobese) with PCOS were recruited for the study. Serum levels of testosterone, LH, FSH, thyroid stimulating hormone (TSH), free thyroxine (free T4) and free triiodothyronine (free T3) levels were measured. Results: Serum LH (p = 0.040), testosterone (p = 0.010) and free triiodothyronine (p = 0.006) levels were significantly elevated in obese PCOS women as compared to non-obese PCOS women. Both LH (r = 0.478, p = 0.002) and free T3 (r = 0.379, p = 0.036) were correlating positively with body mass index (BMI) in obese PCOS subjects. Testosterone was positively associated with duration of infertility in obese PCOS women (R2 = 0.187, â = 0.433, p = 0.005) Conclusion: We conclude that LH, testosterone and free T3 levels are increased with increase in BMI among women with PCOS.


PDF Share
  1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61.
  2. Taponen S, Martikainen H, Jarvelin MR, et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab 2003; 88:141-147.
  3. Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000;52: 595-600.
  4. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003;24:302-312.
  5. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;36:105-111.
  6. Gambineri A, Pelusi C, Vicennati V, et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-896.
  7. Simoni M, Gromoll J, Nieschlag E. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr Rev 1997;18:739-773.
  8. Stricker R, Eberhart R, Chevailler MC, et al. Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 2006;44:883-887.
  9. Woo I, Tobler K, Khafagy A, et al. Predictive Value of Elevated LH/ FSH Ratio for Ovulation Induction in Patients with Polycystic Ovary Syndrome. J Reprod Med 2015;60:495-500.
  10. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245.
  11. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107-117.
  12. Chen MJ, Yang WS, Chen CL, et al. The relationship between anti- Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod 2008;23:952-957.
  13. Fornes R, Hu M, Maliqueo M, Kokosar M, Benrick A, Carr D, et al. Maternal testosterone and placental function: Effect of electroacupuncture on placental expression of angiogenic markers and fetal growth. Mol Cell Endocrinol 2016;433:1-11.
  14. Janssen OE, Mehlmauer N, Hahn S, et al. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150:363-369.
  15. Calvar CE, Bengolea SV, Deutsch SI, et al. [High frequency of thyroid abnormalities in polycystic ovary syndrome]. Medicina (B Aires) 2015;75:213-217.
  16. Yin D, Ruan X, Tian X, et al. The relationship between thyroid function and metabolic changes in Chinese women with polycystic ovary syndrome. Gynecol Endocrinol 2017;33: 332-335.
  17. Tagliaferri V, Romualdi D, Guido M, et al. The link between metabolic features and TSH levels in polycystic ovary syndrome is modulated by the body weight: an euglycaemic-hyperinsulinaemic clamp study. Eur J Endocrinol 2016;175:433-441.
  18. Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 2012;30:496-506.
  19. Chang RJ. The reproductive phenotype in polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab 2007;3:688-695.
  20. Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor - a review. Placenta 2008;29(Suppl B):169-177.
  21. Banaszewska B, Spaczynski RZ, Pelesz M, et al. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. Rocz Akad Med Bialymst 2003;48: 131-134.
  22. Moran C, Garcia-Hernandez E, Barahona E, et al. Relationship between insulin resistance and gonadotropin dissociation in obese and nonobese women with polycystic ovary syndrome. Fertil Steril 2003;80:1466-1472.
  23. Beydoun HA, Beydoun MA, Wiggins N, et al. Relationship of obesity-related disturbances with LH/FSH ratio among postmenopausal women in the United States. Maturitas 2012;71: 55-61.
  24. Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res 2010;1364:186-197.
  25. Wehr E, Moller R, Horejsi R, et al. Subcutaneous adipose tissue topography and metabolic disturbances in polycystic ovary syndrome. Wien Klin Wochenschr 2009;121:262-269.
  26. LaZovic G, Radivojevic U, Milicevic S, et al. Influence of adiposity on leptin, LH and androgen levels in lean, overweight and obese PCOS patients. Int J Fertil Womens Med 2007;52:82-88.
  27. Yasmin E, Balen AH, Barth JH. The association of body mass index and biochemical hyperandrogenaemia in women with and without polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013; 166:173-177.
  28. Trummer C, Schwetz V, Giuliani A, et al. Impact of elevated thyroidstimulating hormone levels in polycystic ovary syndrome. Gynecol Endocrinol 2015;31:819-823.
  29. Mohammed S, Awooda HA, Rayis DA, et al. Thyroid function/ antibodies in sudanese women with polycystic ovarian disease. Obstet Gynecol Sci 2017;60:187-192.
  30. Zimmermann-Belsing T, Brabant G, Holst JJ, et al. Circulating leptin and thyroid dysfunction. Eur J Endocrinol 2003;149:257-271.
  31. Feldt-Rasmussen U. Thyroid and leptin. Thyroid 2007;17: 413-419.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.